Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin

Journal of Pineal Research

Volumn 48, Issue 1, 2010, Pages 55-64

  Chang, Thomas K H ^a   Chen, Jie ^a   Yang, Guixiang ^a   Yeung, Eugene Y H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

7 ethoxyresorufin; Benzo a pyrene; Coumarin; CYP1A1; CYP1A2; CYP1B1; CYP2A6; Melatonin

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BENZO[A]PYRENE; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; MELATONIN;

ARTICLE; BREAST EPITHELIUM; CARCINOGENESIS; CATALYSIS; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME;

ARYL HYDROCARBON HYDROXYLASES; BENZOPYRENES; CELL LINE; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MELATONIN; MICROSOMES, LIVER; OXAZINES; PLASMIDS; POLYMERASE CHAIN REACTION;

EID: 71549130799     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2009.00724.x     Document Type: Article

References (63)

1. William WN Jr., Heymach JV, Kim ES et al. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009 8 : 213 225.
2. Wattenberg LW. Prevention - therapy - basic science and the resolution of the cancer problem: presidential address. Cancer Res 1993 53 : 5890 5896.
3. Stoner GD, Morse MA, Kelloff GJ. Perspectives in cancer chemoprevention. Environ Health Perspect 1997 105 (Suppl 4 945 954.
4. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008 21 : 70 83.
5. Brzezinski A. Melatonin in humans. N Engl J Med 1997 336 : 186 195.
6. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004 25 : 177 195.
7. Korkmaz A, Reiter RJ, Topal T et al. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009 15 : 43 50.
8. Gonzalez A, Cos S, Martinez-Campa C et al. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 2008 45 : 86 92.
9. Korkmaz A, Sanchez-Barcelo EJ, Tan DX et al. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res Treat 2009 115 : 13 27.
10. Paredes SD, Korkmaz A, Manchester LC et al. Phytomelatonin: a review. J Exp Bot 2009 60 : 57 69.
11. Jan JE, Reiter RJ, Wasdell MB et al. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res 2009 46 : 1 7.
12. Chen G, Huo Y, Tan DX et al. Melatonin in Chinese medicinal herbs. Life Sci 2003 73 : 19 26.
13. Aubert C, Janiaud P, Lecalvez J. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J Neural Transm 1980 47 : 121 130.
14. Tamarkin L, Cohen M, Roselle D et al. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat. Cancer Res 1981 41 : 4432 4436.
15. Shah PN, Mhatre MC, Kothari LS. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res 1984 44 : 3403 3407.
16. Subramanian A, Kothari L. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis. Anticancer Drugs 1991 2 : 297 303.
17. Kothari L, Subramanian A. A possible modulatory influence of melatonin on representative phase I and II drug metabolizing enzymes in 9,10-dimethyl-1,2- benzanthracene induced rat mammary tumorigenesis. Anticancer Drugs 1992 3 : 623 628.
18. Kubatka P, Kalicka K, Chamilova M et al. Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma 2002 49 : 255 259.
19. Lenoir V, Yon De Jonage-Canonico MB, Perrin MH et al. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res 2005 7 : R470 R476.
20. Cos S, Gonzalez A, Guezmes A et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 2006 118 : 274 278.
21. Anisimov VN, Zabezhinski MA, Popovich IG et al. Inhibitory effect of melatonin on 7,12-dimethylbenz[a]anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett 2000 156 : 199 205.
22. Vesnushkin GM, Plotnikova NA, Semenchenko AI et al. Dose-dependent inhibitory effect of melatonin on carcinogenesis induced by benzo[a]pyrene in mice. J Exp Clin Cancer Res 2006 25 : 507 513.
23. Reiter RJ, Tan DX, Korkmaz A et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 2007 13 : 303 328.
24. Ioannides C, Lewis DFV. Cytochromes P450 in the bioactivation of chemicals. Curr Top Med Chem 2004 4 : 1767 1788.
25. Shou M, Korzekwa KR, Krausz KW et al. Specificity of cDNA-expressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7,12-dimethylbenz[a]anthracene. Mol Carcinog 1996 17 : 241 249.
26. Shimada T, Gillam EMJ, Sutter TR et al. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 1997 29 : 617 622.
27. Beischlag TV, Morales JL, Hollingshead BD et al. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 2008 18 : 207 250.
28. Raunio H, Hakkola J, Pelkonen O. The CYP2A subfamily. In : Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and Other Xenobiotics. Ioannides C, ed., Royal Society of Chemistry, Cambridge, UK, 2008 pp. 150 177.
29. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998 11 : 559 603.
30. Chen YH, Beischlag TV, Kim JH et al. Role of GAC63 in transcriptional activation mediated by the aryl hydrocarbon receptor. J Biol Chem 2006 281 : 12242 12247.
31. Chang TKH, Chen J, Yeung EYH. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol Appl Pharmacol 2006 213 : 18 26.
32. Waxman DJ, Chang TKH. Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation. Methods Mol Biol 2006 320 : 91 96.
33. Webb JL. Enzyme and Metabolic Inhibitors. Academic Press, New York, 1963.
34. Rajaraman G, Yang G, Chen J et al. Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can J Physiol Pharmacol 2009 87 : 674 683.
35. Chang TKH, Chen J, Pillay V et al. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci 2003 71 : 11 19.
36. Singer VL, Jones LJ, Yue ST et al. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. Anal Biochem 1997 249 : 228 238.
37. Huang Z, Fasco MJ, Figge HL et al. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996 24 : 899 905.
38. Yuan R, Madani S, Wei XX et al. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002 30 : 1311 1319.
39. Chang TKH, Chen J, Lee WBK. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001 299 : 874 882.
40. Ciolino HP, Yeh GC. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 1999 56 : 760 767.
41. Chang TKH, Lee WBK, Ko HH. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can J Physiol Pharmacol 2000 78 : 874 881.
42. +2 in the MCF-10A human mammary epithelial cell line by carcinogenic polycyclic aromatic hydrocarbons. Mol Carcinog 1999 25 : 48 54.
43. Lee JE, Safe S. 3′,4′-Dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells. Toxicol Sci 2000 58 : 235 242. (Pubitemid 32042422)
44. Yeleswaram K, Vachharajani N, Santone K. Involvement of cytochrome P-450 isozymes in melatonin metabolism and clinical implications [letter]. J Pineal Res 1999 26 : 190 191.
45. Pastrakuljic A, Tang BK, Roberts EA et al. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 1997 53 : 531 538.
46. Agundez JAG, Gallardo L, Martinez C et al. Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics 1998 8 : 251 258.
47. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003 43 : 309 334.
48. Skene DJ, Papagiannidou E, Hashemi E et al. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J Pineal Res 2001 31 : 333 342.
49. Semak I, Korik E, Antonova M et al. Metabolism of melatonin by cytochrome P450s in rat liver mitochondria and microsomes. J Pineal Res 2008 45 : 515 523.
50. Facciola G, Hidestrand M, Von Bahr C et al. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001 56 : 881 888.
51. Ma X, Idle R, Krausz KW et al. Metabolism of melatonin by human cytochromes P450. Drug Metab Dispos 2005 33 : 489 494.
52. Schwarz D, Roots I. In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. Biochem Biophys Res Commun 2003 303 : 902 907.
53. Luch A. Nature and nurture - lessions from chemical carcinogenesis. Nat Rev Cancer 2005 5 : 113 125.
54. Kim D, Guengerich FP. Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 2005 45 : 27 49.
55. Ursing C, Von Bahr C, Brismar K et al. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol 2005 61 : 197 201.
56. Waldhauser F, Waldhauser M, Lieberman HR et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984 39 : 307 313.
57. Mcfadyen MCE, Murray GI. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol 2005 1 : 259 263.
58. Sindhu RK, Wagner FE, Kikkawa Y. Induction of cytochrome P450 1A1 and 1B1 by photooxidized tryptophan in transformed human keratinocytes. Adv Exp Med Biol 2003 527 : 297 306.
59. Spink BC, Hussain MM, Katz BH et al. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem Pharmacol 2003 66 : 2313 2321.
60. Hu W, Sorrentino C, Denison MS et al. Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 2007 71 : 1475 1486.
61. Rowlands JC, He L, Hakkak R et al. Soy and whey proteins downregulate DMBA-induced liver and mammary gland CYP1 expression in female rats. J Nutr 2001 131 : 3281 3287.
62. Praast G, Bartsch C, Bartsch H et al. Hepatic hydroxylation of melatonin in the rat is induced by phenobarbital and 7,12-dimethylbenz[a]anthracene - implication for cancer etiology. Experientia 1995 51 : 349 355.
63. Bartsch C, Bartsch H, Lippert TH et al. Effect of the mammary carcinogen 7,12-dimethylbenz[a]anthracene on pineal melatonin biosynthesis, secretion and peripheral metabolism. Neuroendocrinology 1990 52 : 538 544.